Pay in 4 interest-free payments of $33.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
BAY-1797 treatment shows the AUCnorm
thereby inhibiting deacetylation of histones and HDAC4 client transcription factors
JP83 was found to be able to inhibit FAAH with equal or greater potency than URB597
50 and 100 µM
Ensitrelvir - CAS# 2647530-73-0 hyl 3 4 5-trimethoxybenzoate BAY-1797 treatment shows the AUCnormEnsitrelvir, CAS No. 2647530 73 0 , also known as S 217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C like protease inhibitor for the treatment of COVID 19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non covalent, non peptidic, SARS CoV 2 3CL protease inhibitor (IC50=13 nM). It
US$ 400.00
US$ 1400.00
US$ 1200.00
US$ 1000.00
US$ 1400.00
US$ 400.00
US$ 1000.00
US$ 600.00
US$ 1000.00
US$ 1200.00
US$ 600.00
US$ 1200.00
US$ 400.00
US$ 1400.00
US$ 800.00
US$ 600.00
US$ 800.00
US$ 1000.00